(NASDAQ:LGND) rating on Wednesday, September 30. Investors sentiment decreased to 1.08 in 2016 Q4. Its down 0.02, from 0.91 in 2016Q3. The current share price indicates that stock is -17.19% away from its one year high and is moving …
$4.13 million worth of Ligand Pharmaceuticals Inc. The stock declined 1.36% or $0.73 reaching $52.87 on the news. The target implies a 20.15% spike from where the shares are now trading. Ligand Pharmaceuticals Incorporated …
At the first glance of LGND, I was so shocked. It was not only because of the stunning collaborations and the pipeline, but also the unbelievable low stock price which was far undervalued. *DARA(PS433540) is leading independent program of …
Ligand Pharmaceuticals Inc. (LGND) ended long rallies around the $120 level in 1996, 2000, 2002 and 2004 so it wasn’t a surprise when the most recent uptick ran into a buzzsaw of selling pressure after the stock traded above the magic …
Stock market analysts watching Ligand Pharmaceuticals Incorporated (LGND) have recently changed their ratings on the stock. The latest reports which are outstanding on Monday 31st of July state 1 analyst has a rating of “strong buy”, 3 …
That creates more demand for the stock, which pushes it higher, which forces more shorts to buy the shares and so on and so on. Look at Ligand Pharmaceuticals Inc. (NASDAQ:LGND). The stock has had a big run this year, especially …
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it will receive $10 million from a contractually specified royalty rate buy-down following the sale by CorMatrix Cardiovascular, Inc. of rights to its commercial pericardial repair …
The company was initiated on Wednesday, April 13 by Stephens. On Monday, September 21 the stock rating was maintained by Roth Capital with "Buy". TH Capital maintained the shares of LGND in report on Friday, December 18 …
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) opened at 115.00 on Thursday. The stock has "Buy" rating by TH Capital on Friday, December 18. (NASDAQ:LGND) on Thursday, November 19 with "Buy" rating. On Thursday, …
Ligand generates revenues in the form of royalties, license and milestone payments and sale of Captisol material. The company’s Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. …